{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:39:58Z","timestamp":1787701198304,"version":"build-2784847793"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.blre.2020.100732","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:23:32Z","timestamp":1594337012000},"page":"100732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity"],"prefix":"10.1016","volume":"46","author":[{"given":"Benjamin T.","family":"Diamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even","family":"Rustad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Thoren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.blre.2020.100732_bb0005","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100732_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.21273","article-title":"Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient","volume":"90","author":"Landgren","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0025","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.blre.2020.100732_bb0030","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.blre.2020.100732_bb0040","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0045","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100732_bb0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2020.100732_bb0055","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0060","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.128215","article-title":"Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen","volume":"101","author":"de Tute","year":"2016","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.blre.2020.100732_bb0065","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100732_bb0070","first-page":"126(23)","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100732_bb0075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0080","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3324\/haematol.2014.115162","article-title":"The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma","volume":"100","author":"Paiva","year":"2015","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.blre.2020.100732_bb0085","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0090","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100732_bb0095","article-title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)","volume":"132","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100732_bb0100","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","author":"Avet-Loiseau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.blre.2020.100732_bb0105","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.blre.2020.100732_bb0110","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100732_bb0115","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124191","article-title":"Expanded meta-analyses confirms the association between MRD and long-term survival outcomes in multiple myeloma (MM)","author":"Munshi","year":"2019","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2020.100732_bb0120","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0125","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.23546","article-title":"Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma","volume":"113","author":"Barlogie","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0130","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.blre.2020.100732_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211600","article-title":"Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma","volume":"14","author":"Rustad","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2020.100732_bb0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates","volume":"442","author":"Delgado","year":"2017","journal-title":"J Immunol Methods"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0145","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","article-title":"Phenotypic difference of normal plasma cells from mature myeloma cells","volume":"81","author":"Harada","year":"1993","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100732_bb0150","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2020.100732_bb0155","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0160","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0165","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2020.100732_bb0170","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0175","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"Flanders","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0180","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2020.100732_bb0185","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2004.05120.x","article-title":"Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma","volume":"126","author":"Bakkus","year":"2004","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0190","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0195","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminhematol.2018.02.007","article-title":"Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions","volume":"55","author":"Ho","year":"2018","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0205","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ajh.25641","article-title":"Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma","volume":"94","author":"Rustad","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0210","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/leu.2015.7","article-title":"The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution","volume":"29","author":"Puig","year":"2015","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.blre.2020.100732_bb0215","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0220","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2020.100732_bb0225","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124645","article-title":"Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients","author":"Oliva","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.26","article-title":"Meeting report: advances in minimal residual disease testing in multiple myeloma 2018","volume":"2","author":"Landgren","year":"2019","journal-title":"Adv Cell Gene Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100732_bb0235","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2018-99-118768","article-title":"Capture rate of the adaptive next generation sequencing VDJ assay in multiple myeloma","volume":"132","author":"Hultcrantz","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jmoldx.2016.08.004","article-title":"A next-generation sequencing strategy for evaluating the most common genetic abnormalities in multiple myeloma","volume":"19","author":"Jim\u00e9nez","year":"2017","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.blre.2020.100732_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.72","article-title":"A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma","volume":"6","author":"Bolli","year":"2016","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.blre.2020.100732_bb0255","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system","volume":"107","author":"Dingli","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100732_bb0260","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0265","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0270","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.blre.2020.100732_bb0280","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0290","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.beha.2020.101142","article-title":"Tracking of low disease burden in multiple myeloma: using mass spectrometry assays in peripheral blood","volume":"33","author":"Chapman","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2020.100732_bb0295","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma","author":"Eveillard","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2020.100732_bb0300","article-title":"Qip-mass spectrometry in high risk smoldering multiple myeloma patients included in the GEM-CESAR trial: comparison with conventional and minimal residual disease IMWG response assessment","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","article-title":"Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model","volume":"122","author":"Kim","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2020.100732_bb0310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphys.2017.00149","article-title":"Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma","volume":"8","author":"Kendrick","year":"2017","journal-title":"Front Physiol"},{"issue":"8","key":"10.1016\/j.blre.2020.100732_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.blre.2020.100732_bb0325","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.blre.2020.100732_bb0330","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0335","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2020.100732_bb0340","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100732_bb0345","first-page":"126(23)","article-title":"Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100732_bb0350","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0355","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"7","key":"10.1016\/j.blre.2020.100732_bb0360","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2020.100732_bb0365","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2020.100732_bb0370","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.blre.2020.100732_bb0375","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0380","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0385","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0390","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992\u20132004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2020.100732_bb0395","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0400","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.blre.2020.100732_bb0405","article-title":"Incidence and survival outcomes of extramedullary myeloma","volume":"122","author":"Ghimire","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2020.100732_bb0410","article-title":"Comparison of plasma cell infiltration in random samples of the bone marrow and osteolyses acquired by CT-guided biopsy in patients with symptomatic multiple myeloma","volume":"34","author":"Hillengass","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0415","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11 C-choline vs. 18 F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J Surg Oncol"},{"issue":"11","key":"10.1016\/j.blre.2020.100732_bb0420","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.blre.2020.100732_bb0425","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.blre.2020.100732_bb0430","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4\u2032-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann Nucl Med"},{"issue":"43","key":"10.1016\/j.blre.2020.100732_bb0435","doi-asserted-by":"crossref","first-page":"20485","DOI":"10.1039\/C9NR06512A","article-title":"Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma","volume":"11","author":"Detappe","year":"2019","journal-title":"Nanoscale"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100732_bb0440","first-page":"203","article-title":"Preclinical development and first-in-human imaging of 89Zr-daratumumab for CD38 targeted imaging of myeloma","volume":"60","author":"Ulaner","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100732_bb0445","doi-asserted-by":"crossref","first-page":"101149","DOI":"10.1016\/j.beha.2020.101149","article-title":"Monitoring minimal residual disease in the bone marrow using next generation sequencing","volume":"33","author":"Rustad","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0450","first-page":"559","article-title":"Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time","volume":"17","author":"Kazandjian","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100732_bb0455","first-page":"435","article-title":"Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2020.100732_bb0460","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/bloodadvances.2019032276","article-title":"Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition","volume":"3","author":"Pianko","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2020.100732_bb0465","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125842","article-title":"Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: a clinical and correlative phase 2 study","author":"Landgren","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0470","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clml.2019.09.069","article-title":"Sequential minimal residual disease (MRD) monitoring: results from the UK Myeloma XI trial","volume":"19","author":"De Tute","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2020.100732_bb0475","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.blre.2020.100732_bb0480","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10068","key":"10.1016\/j.blre.2020.100732_bb0485","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.blre.2020.100732_bb0490","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.blre.2020.100732_bb0495","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2020.100732_bb0500","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100732_bb0505","series-title":"61st annual meeting and exposition (December 7-10, 2019)","author":"Costa","year":"2019"},{"issue":"12","key":"10.1016\/j.blre.2020.100732_bb0510","doi-asserted-by":"crossref","first-page":"E502","DOI":"10.1002\/ajh.24540","article-title":"Myeloma minimal residual disease testing in the United States: evidence of improved standardization","volume":"91","author":"Salem","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100732_bb0515","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jcm6100091","article-title":"Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation","volume":"6","author":"Takamatsu","year":"2017","journal-title":"J Clin Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:18Z","timestamp":1759436778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":103,"alternative-id":["S0268960X20300825"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100732","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100732"}}